Dasatinib Monohydrate (BMS-354825): A Multitargeted ABL Kinase Inhibitor for CML and Translational Oncology

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a multitargeted ATP-competitive kinase inhibitor with nanomolar potency against ABL, SRC, KIT, and PDGFR kinases (ApexBio). It is effective against wild-type and imatinib-resistant BCR-ABL isoforms, making it indispensable in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) leukemia research. In vitro, Dasatinib demonstrates broad antiproliferative effects in both hematological and solid tumor cell lines; in vivo, it significantly reduces disease burden in BCR-ABL mutant mouse models (Shapira-Netanelov et al., 2025). Its clinical approval since 2006 and compatibility with patient-derived assembloid models have enabled translational advances in resistance mechanism studies and personalized therapy optimization.

Biological Rationale

Chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are driven by dysregulated tyrosine kinase signaling, particularly the BCR-ABL fusion protein. Resistance to first-line treatments, such as imatinib, arises from kinase domain mutations and microenvironmental influences (Shapira-Netanelov et al., 2025). Research tools that inhibit both wild-type and mutant BCR-ABL, as well as associated kinases like SRC, are essential for dissecting these resistance mechanisms and for developing more effective therapies. Advanced assembloid models, which integrate tumor organoids with autologous stromal cell subpopulations, further highlight the necessity for compounds like Dasatinib that can interrogate both tumor-intrinsic and microenvironmental pathways.

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate (BMS-354825) is an ATP-competitive inhibitor targeting ABL, SRC, KIT, and PDGFR families of tyrosine kinases. Its molecular weight is 506.02 g/mol, with the chemical formula C₂₂H₂₈ClN₇O₃S (ApexBio). Dasatinib binds to the active site of target kinases, preventing phosphorylation and downstream signaling required for proliferation and survival of malignant cells. It achieves IC₅₀ values of 0.55 nM for Src and 3.0 nM for Bcr-Abl kinases. The compound is effective against both nonmutated and imatinib-resistant BCR-ABL isoforms, including T315I and Y253F mutants. Dasatinib's multitargeted profile enables the simultaneous disruption of parallel oncogenic pathways, which is critical for overcoming resistance in complex tumor microenvironments (Related Article). This article builds on prior mechanistic summaries by detailing application parameters and resistance context in assembloid systems.

Evidence & Benchmarks

• Dasatinib Monohydrate inhibits Src-family kinases with an IC₅₀ of 0.55 nM and BCR-ABL with 3.0 nM in cell-free biochemical assays (ApexBio).
• Demonstrates antiproliferative activity in hematological and solid tumor cell lines, with pronounced effects in CML and Ph+ ALL models (Shapira-Netanelov et al., 2025).
• Reduces bioluminescent tumor burden in BCR-ABL mutant mouse models after short-term dosing with 25–50 mg/kg/day, administered at 20–25°C storage stability (Shapira-Netanelov et al., 2025).
• Clinically approved by the FDA since 2006 for all phases of CML and Ph+ ALL, with established safety and efficacy benchmarks in human trials (FDA).
• Maintains in vitro potency and selectivity when integrated into patient-derived assembloid tumor models, supporting advanced drug screening and resistance mechanism elucidation (Shapira-Netanelov et al., 2025).

Applications, Limits & Misconceptions

Dasatinib Monohydrate is a cornerstone tool for research in:

• Chronic myeloid leukemia (CML) and Ph+ ALL: Dissection of kinase signaling, drug resistance, and therapeutic response.
• Solid tumor and assembloid models: Analysis of tumor-stroma interactions and personalized drug responsiveness (Dasatinib Monohydrate in Next-Generation Tumor Microenvir...—This article extends previous mechanistic insight by specifying quantitative benchmarks in assembloid systems).
• Kinase pathway interrogation: Simultaneous targeting of ABL, SRC, KIT, and PDGFR kinases.

Common Pitfalls or Misconceptions

• Dasatinib is not selective for a single kinase: Its multitarget profile is essential for efficacy but may confound attribution to a single pathway.
• It does not overcome all resistance mutations: Certain rare BCR-ABL mutants (e.g., T315I) may require alternative strategies (Dasatinib Monohydrate in Microenvironment-Driven Resistan...—This article clarifies boundaries where Dasatinib is insufficient).
• Not suitable for all cancer types: Efficacy in non-Ph+ tumors is context-dependent and must be empirically validated.
• Stability constraints: Dasatinib solutions are stable short-term; long-term storage in solution at -20°C is not recommended due to degradation risk.
• Insolubility in water and ethanol: Only DMSO (≥25.3 mg/mL) should be used for stock preparations.

Workflow Integration & Parameters

Solubility and Storage: Prepare Dasatinib Monohydrate stocks in DMSO at concentrations up to 25.3 mg/mL. It is insoluble in ethanol and water. Store powder at -20°C; use solutions promptly to maintain activity (ApexBio).

Assay Integration: For in vitro kinase or cell-based assays, typical working concentrations range from 1–100 nM. In vivo, dosing regimens of 25–50 mg/kg/day in mouse models are standard for CML/Ph+ ALL xenografts. Always validate activity in the context of assembloid or organoid models, as stromal components can modulate drug response (Shapira-Netanelov et al., 2025).

Interoperability: The B5954 kit is compatible with next-generation assembloid workflows for drug screening and resistance pathway studies. For applications in microenvironment-driven resistance, see Redefining Translational Oncology: Mechanistic Insights a..., which this article updates with quantitative performance benchmarks.

Conclusion & Outlook

Dasatinib Monohydrate (BMS-354825) is a validated, multitargeted ABL kinase inhibitor with robust preclinical and clinical data supporting its use in CML, Ph+ ALL, and advanced translational oncology research. Its compatibility with assembloid models and resistance studies positions it as a critical reagent for next-generation drug discovery. Future directions include leveraging its multitarget efficacy to design more effective combination therapies and integrating single-cell and spatial transcriptomics to further dissect resistance mechanisms (Shapira-Netanelov et al., 2025).

For detailed product specifications and ordering, see the Dasatinib Monohydrate product page.